BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 21810837)

  • 1. Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and/or derepressed AmpC β-lactamase-producing Enterobacteriaceae.
    Balakrishnan I; Awad-El-Kariem FM; Aali A; Kumari P; Mulla R; Tan B; Brudney D; Ladenheim D; Ghazy A; Khan I; Virgincar N; Iyer S; Carryn S; Van de Velde S
    J Antimicrob Chemother; 2011 Nov; 66(11):2628-31. PubMed ID: 21810837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. beta-Lactams without a suicide inhibitor.
    Giamarellou H
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():194-7. PubMed ID: 18154547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy of cefmetazole against pyelonephritis caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae.
    Doi A; Shimada T; Harada S; Iwata K; Kamiya T
    Int J Infect Dis; 2013 Mar; 17(3):e159-63. PubMed ID: 23140947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Temocillin versus carbapenems for urinary tract infection due to ESBL-producing Enterobacteriaceae: a multicenter matched case-control study.
    Delory T; Gravier S; Le Pluart D; Gaube G; Simeon S; Davido B; Piet E; Lepeule R; Lesprit P; Lafaurie M
    Int J Antimicrob Agents; 2021 Jul; 58(1):106361. PubMed ID: 34000372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of temocillin against prevalent ESBL- and AmpC-producing Enterobacteriaceae from south-east England.
    Livermore DM; Hope R; Fagan EJ; Warner M; Woodford N; Potz N
    J Antimicrob Chemother; 2006 May; 57(5):1012-4. PubMed ID: 16531428
    [No Abstract]   [Full Text] [Related]  

  • 6. Assessment of the clinical significance of production of extended-spectrum beta-lactamases (ESBL) by Enterobacteriaceae.
    Henshke-Bar-Meir R; Yinnon AM; Rudensky B; Attias D; Schlesinger Y; Raveh D
    Infection; 2006 Apr; 34(2):66-74. PubMed ID: 16703295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Doripenem activity tested against a global collection of Enterobacteriaceae, including isolates resistant to other extended-spectrum agents.
    Mendes RE; Rhomberg PR; Bell JM; Turnidge JD; Sader HS
    Diagn Microbiol Infect Dis; 2009 Apr; 63(4):415-25. PubMed ID: 19249175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended-spectrum beta-lactamase-producing organisms.
    Falagas ME; Karageorgopoulos DE
    J Hosp Infect; 2009 Dec; 73(4):345-54. PubMed ID: 19596491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bacteremia due to extended-spectrum beta-lactamase-producing Enterobacteriaceae other than Escherichia coli and Klebsiella.
    Huang SS; Lee MH; Leu HS
    J Microbiol Immunol Infect; 2006 Dec; 39(6):496-502. PubMed ID: 17164953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular characteristics of extended-spectrum β-lactamases in clinical isolates of Enterobacteriaceae from the Philippines.
    Kanamori H; Navarro RB; Yano H; Sombrero LT; Capeding MR; Lupisan SP; Olveda RM; Arai K; Kunishima H; Hirakata Y; Kaku M
    Acta Trop; 2011; 120(1-2):140-5. PubMed ID: 21820398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of temocillin against prevalent extended-spectrum beta-lactamases producing Enterobacteriaceae from Belgian intensive care units.
    Glupczynski Y; Huang TD; Berhin C; Claeys G; Delmée M; Ide L; Ieven G; Pierard D; Rodriguez-Villalobos H; Struelens M; Vaneldere J
    Eur J Clin Microbiol Infect Dis; 2007 Nov; 26(11):777-83. PubMed ID: 17668253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome of urinary tract infections caused by extended spectrum β-lactamase-producing Enterobacteriaceae in children.
    Tratselas A; Iosifidis E; Ioannidou M; Saoulidis S; Kollios K; Antachopoulos C; Sofianou D; Roilides EJ
    Pediatr Infect Dis J; 2011 Aug; 30(8):707-10. PubMed ID: 21248655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ertapenem for the treatment of urinary tract infections caused by extended-spectrum β-lactamase-producing bacteria in children.
    Dalgic N; Sancar M; Bayraktar B; Dincer E; Pelit S
    Scand J Infect Dis; 2011 May; 43(5):339-43. PubMed ID: 21271945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of temocillin against extended spectrum beta-lactamase-producing Escherichia coli.
    Rodriguez-Villalobos H; Malaviolle V; Frankard J; de Mendonça R; Nonhoff C; Struelens MJ
    J Antimicrob Chemother; 2006 Apr; 57(4):771-4. PubMed ID: 16501056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of newer beta-lactamases in gram-negative clinical isolates collected in the United States from 2001 to 2002.
    Moland ES; Hanson ND; Black JA; Hossain A; Song W; Thomson KS
    J Clin Microbiol; 2006 Sep; 44(9):3318-24. PubMed ID: 16954267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-carbapenem therapy of urinary tract infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae.
    de La Blanchardière A; Dargère S; Guérin F; Daurel C; Saint-Lorant G; Verdon R; Cattoir V
    Med Mal Infect; 2015 May; 45(5):169-72. PubMed ID: 25845927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-intravenous carbapenem-sparing antibiotics for definitive treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamase (ESBL) or AmpC β-lactamase: A propensity score study.
    Meije Y; Pigrau C; Fernández-Hidalgo N; Clemente M; Ortega L; Sanz X; Loureiro-Amigo J; Sierra M; Ayestarán A; Morales-Cartagena A; Ribera A; Duarte A; Abelenda G; Rodríguez-Baño J; Martínez-Montauti J
    Int J Antimicrob Agents; 2019 Aug; 54(2):189-196. PubMed ID: 31075401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Which proportion of extended-spectrum beta-lactamase producing strains could be treated by non-carbapenem beta-lactams?
    Canoui E; Tankovic J; Bige N; Alves M; Offenstadt G
    Med Mal Infect; 2014 May; 44(5):235-7. PubMed ID: 24780641
    [No Abstract]   [Full Text] [Related]  

  • 19. Cefepime versus carbapenems for the treatment of urinary tract infections caused by extended-spectrum β-lactamase-producing enterobacteriaceae.
    Kim SA; Altshuler J; Paris D; Fedorenko M
    Int J Antimicrob Agents; 2018 Jan; 51(1):155-158. PubMed ID: 28943367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Extended-spectrum beta-lactamase producing-enterobacteriaceae].
    Mariani-Kurkdjian P; Doit C; Bingen E
    Arch Pediatr; 2012 Nov; 19 Suppl 3():S93-6. PubMed ID: 23178141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.